ACB Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of -58.83% compared to Aurora Cannabis, Inc.'s net margin of 42.95%. Aurora Cannabis, Inc.'s return on equity of -10.76% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Aurora Cannabis, Inc. has a consensus price target of $6.34, signalling upside risk potential of 38.63%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 8.86%. Given that Aurora Cannabis, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Aurora Cannabis, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Aurora Cannabis, Inc. has a beta of 0.243, which suggesting that the stock is 75.662% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

Aurora Cannabis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurora Cannabis, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Aurora Cannabis, Inc. quarterly revenues are $65.6M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Aurora Cannabis, Inc.'s net income of -$38.6M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Aurora Cannabis, Inc.'s price-to-earnings ratio is 103.35x while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurora Cannabis, Inc. is 0.97x versus 8.13x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Instadose Pharma Corp. has a net margin of -58.83% compared to Aurora Cannabis, Inc.'s net margin of --. Aurora Cannabis, Inc.'s return on equity of -10.76% beat Instadose Pharma Corp.'s return on equity of --.

Aurora Cannabis, Inc. has a consensus price target of $6.34, signalling upside risk potential of 38.63%. On the other hand Instadose Pharma Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Aurora Cannabis, Inc. has higher upside potential than Instadose Pharma Corp., analysts believe Aurora Cannabis, Inc. is more attractive than Instadose Pharma Corp..

Aurora Cannabis, Inc. has a beta of 0.243, which suggesting that the stock is 75.662% less volatile than S&P 500. In comparison Instadose Pharma Corp. has a beta of -714.392, suggesting its less volatile than the S&P 500 by 71539.203%.

Aurora Cannabis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instadose Pharma Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurora Cannabis, Inc. pays -- of its earnings as a dividend. Instadose Pharma Corp. pays out -- of its earnings as a dividend.

Aurora Cannabis, Inc. quarterly revenues are $65.6M, which are larger than Instadose Pharma Corp. quarterly revenues of --. Aurora Cannabis, Inc.'s net income of -$38.6M is higher than Instadose Pharma Corp.'s net income of --. Notably, Aurora Cannabis, Inc.'s price-to-earnings ratio is 103.35x while Instadose Pharma Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurora Cannabis, Inc. is 0.97x versus -- for Instadose Pharma Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -58.83% compared to Aurora Cannabis, Inc.'s net margin of --. Aurora Cannabis, Inc.'s return on equity of -10.76% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Aurora Cannabis, Inc. has a consensus price target of $6.34, signalling upside risk potential of 38.63%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 505.14%. Given that Oncolytics Biotech, Inc. has higher upside potential than Aurora Cannabis, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Aurora Cannabis, Inc..

Aurora Cannabis, Inc. has a beta of 0.243, which suggesting that the stock is 75.662% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Aurora Cannabis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurora Cannabis, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Aurora Cannabis, Inc. quarterly revenues are $65.6M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Aurora Cannabis, Inc.'s net income of -$38.6M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Aurora Cannabis, Inc.'s price-to-earnings ratio is 103.35x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurora Cannabis, Inc. is 0.97x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tilray Brands, Inc. has a net margin of -58.83% compared to Aurora Cannabis, Inc.'s net margin of 0.72%. Aurora Cannabis, Inc.'s return on equity of -10.76% beat Tilray Brands, Inc.'s return on equity of -84.8%.

Aurora Cannabis, Inc. has a consensus price target of $6.34, signalling upside risk potential of 38.63%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $17.83 which suggests that it could grow by 152.6%. Given that Tilray Brands, Inc. has higher upside potential than Aurora Cannabis, Inc., analysts believe Tilray Brands, Inc. is more attractive than Aurora Cannabis, Inc..

Aurora Cannabis, Inc. has a beta of 0.243, which suggesting that the stock is 75.662% less volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 1.758, suggesting its more volatile than the S&P 500 by 75.794%.

Aurora Cannabis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurora Cannabis, Inc. pays -- of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend.

Aurora Cannabis, Inc. quarterly revenues are $65.6M, which are smaller than Tilray Brands, Inc. quarterly revenues of $209.5M. Aurora Cannabis, Inc.'s net income of -$38.6M is lower than Tilray Brands, Inc.'s net income of $1.5M. Notably, Aurora Cannabis, Inc.'s price-to-earnings ratio is 103.35x while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurora Cannabis, Inc. is 0.97x versus 8.10x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.